Medaria en es it fr

Medaria Brand names, Medaria Analogs

Medaria Brand Names Mixture

  • No information avaliable

Medaria Chemical_Formula


Medaria RX_link

Medaria fda sheet

Medaria FDA

Medaria msds (material safety sheet)

Medaria Synthesis Reference

No information avaliable

Medaria Molecular Weight

279.848 g/mol

Medaria Melting Point

191-192 oC

Medaria H2O Solubility

2.9 mg/mL (in pH 5.2 water)

Medaria State


Medaria LogP


Medaria Dosage Forms


Medaria Indication

For the treatment of obesity.

Medaria Pharmacology

Sibutramine is an orally administered agent for the treatment of obesity. Sibutramine exerts its pharmacological actions predominantly via its secondary (M1) and primary (M2) amine metabolites. The parent compound, sibutramine, is a potent inhibitor of serotonin and norepinephrine reuptake in vivo, but not in vitro. However, metabolites M1 and M2 inhibit the reuptake of these neurotransmitters both in vitro and in vivo. In human brain tissue, M1 and M2 also inhibit dopamine reuptake in vitro, but with ~3-fold lower potency than for the reuptake inhibition of serotonin or norepinephrine. Sibutramine, M1 and M2 exhibit no evidence of anticholinergic or antihistaminergic actions. In addition, receptor binding profiles show that sibutramine, M1 and M2 have low affinity for serotonin (5-HT1, 5-HT1A, 5-HT1B, 5-HT2A, 5-HT2C), norepinephrine (b, b1, b3, a1 and a2), dopamine (D1 and D2), benzodiazepine, and glutamate (NMDA) receptors. These compounds also lack monoamine oxidase inhibitory activity in vitro and in vivo.

Medaria Absorption

Rapid absorption following oral administration. Absolute bioavailability is not known, but at least 77% of a single oral dose of sibutramine is absorbed.

Medaria side effects and Toxicity

Side effects include dry mouth, anorexia, insomnia, constipation and headache.

Medaria Patient Information


Medaria Organisms Affected

Humans and other mammals